tiprankstipranks
Trending News
More News >
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
US Market

Protagonist Therapeutics (PTGX) Ownership - Who Owns Protagonist Therapeutics?

Compare
653 Followers

Protagonist Therapeutics (PTGX) Ownership Overview

1.72%15.73%0.13%23.30%59.12%
0.13% Other Institutional Investors
23.30% ETFs
59.12% Public Companies and
Individual Investors
The ownership structure of Protagonist Therapeutics (PTGX) stock is a mix of institutional, retail, and individual investors. Approximately 39.16% of the company’s stock is owned by Institutional Investors, 1.72% is owned by Insiders, and 59.12% is owned by Public Companies and Individual Investors.
The ownership structure of Protagonist Therapeutics (PTGX) stock is a mix of institutional, retail, and individual investors. Approximately 15.86% of the company’s stock is owned by Institutional Investors, 1.72% is owned by Insiders, and 23.30% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Mar 14, 2025
xxxxxxxxxxxxx
$1462553
Mar 14, 2025
xxxxxxxxxxxxx
$1700850
Feb 20, 2025
xxxxxxxxxxxxx
$204607
Nov 27, 2024
xxxxxxxxxxxxx
$1414402

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Dec 31, 2024
xxxxxxxxxxxxx
$4053000
Dec 31, 2024
xxxxxxxxxxxxx
$13112342
Dec 31, 2024
xxxxxxxxxxxxx
$22477822
Dec 31, 2024
xxxxxxxxxxxxx
$49086153

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
7,015,401Institution11.43%329,373,077
5,930,006Institution9.66%278,413,782
3,551,749Institution5.79%166,754,616
2,752,858Institution4.48%129,246,683
1,501,275Institution2.45%70,484,861
1,271,662Institution2.07%59,704,531
1,038,563Institution1.69%48,760,533
931,890Institution1.52%43,752,236
621,481Institution1.01%29,178,533
592,115Institution0.96%27,799,799

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
2,752,858Institution4.48%129,246,683
1,038,563Institution1.69%48,760,533
621,481Institution1.01%29,178,533
592,115Institution0.96%27,799,799
423,913Institution0.69%19,902,715
414,318Institution0.67%19,452,230
345,217Institution0.56%16,207,938
334,459Institution0.54%15,702,850
286,788Institution0.47%13,464,697
247,781Institution0.40%11,633,318

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
3,643,544Institution5.94%171,064,391
1,864,255Institution3.04%70,077,345
1,514,124Institution2.47%71,088,122
901,964Institution1.47%33,904,827
552,928Institution0.90%24,898,348
540,988Institution0.88%25,399,387
533,679Institution0.87%25,056,229
511,708Institution0.83%23,042,211
433,681Institution0.71%20,361,323
372,319Institution0.61%17,480,377

FAQ

Who Owns Protagonist Therapeutics (PTGX)?
According to the latest TipRanks data, approximately 0.13% of the company's stock is held by institutional investors, 1.72% is held by insiders, and 59.12% is held by retail investors.
    What percentage of Protagonist Therapeutics (PTGX) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 0.13% of Protagonist Therapeutics (PTGX) stock is held by institutional investors.
      What percentage of Protagonist Therapeutics (PTGX) stock is held by retail investors?
      According to the latest TipRanks data, approximately 59.12% of Protagonist Therapeutics (PTGX) stock is held by retail investors.
        Who owns the most shares of Protagonist Therapeutics (PTGX)?
        iShares owns the most shares of Protagonist Therapeutics (PTGX).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis